Challenges of quantification of TSPO in the human brain

Clinical and Translational Imaging

Volumn 3, Issue 6, 2015, Pages 403-416

  Hinz, Rainer ^a   Boellaard, Ronald ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Positron emission tomography (PET); Quantification; Translocator protein 18 kDa (TSPO); 11C PK11195

Indexed keywords

BENZODIAZEPINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; TRANSCRIPTION FACTOR;

ALZHEIMER DISEASE; AUTORADIOGRAPHY; BRAIN; CEREBELLUM; CLUSTER ANALYSIS; COGNITIVE DEFECT; CORRELATION COEFFICIENT; DEMENTIA; HISTOLOGY; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; SOLID PHASE EXTRACTION; TEST RETEST RELIABILITY; THIN LAYER CHROMATOGRAPHY;

EID: 84952993526     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-015-0138-7     Document Type: Review

References (70)

1. Charbonneau P, Syrota A, Crouzel C, Valois JM, Prenant C, Crouzel M (1986) Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. Circulation 73:476–483. doi:10.1161/01.CIR.73.3.476
2. Bergström M, Mosskin M, Ericson K, Ehrin E, Thorell JO, von Holst H, Norén G, Persson A, Halldin C, Stone-Elander S (1986) Peripheral benzodiazepine binding sites in human gliomas evaluated with positron emission tomography. Acta Radiol Suppl 369:409–411
3. Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett DM, McKeever PE, Wieland DM, Kilbourn MR, Starosta-Rubinstein S, Mancini WR, Kuhl DE, Greenberg HS, Young AB (1989) PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol 26:752–758. doi:10.1002/ana.410260611
4. Ramsay SC, Weiller C, Myers R, Cremer JE, Luthra SK, Lammertsma AA, Frackowiak RS (1992) Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet 339:1054–1055. doi:10.1016/0140-6736(92)90576-O
5. Blomqvist G, Pauli S, Farde L, Eriksson L, Persson A, Halldin C (1989) Dynamic models of reversible ligand binding. In: Beckers C, Goffinet A, Bol A (eds) Positron emission tomography in clinical research and clinical diagnosis: tracer modelling and radioreceptors. Kluwer Academic Publishers, Dardrecht, pp 35–44. ISBN 0-7923-0254-0
6. Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, Jones AKP (1991) Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. J Cereb Blood Flow Metab 11:1–9. doi:10.1038/jcbfm.1991.1
7. 11C] raclopride studies. J Cereb Blood Flow Metab 16:42–52. doi:10.1097/00004647-199601000-00005
8. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158. doi:10.1006/nimg.1996.0066
9. Logan J, Fowler JS, Volkow ND, Wang G-J, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840. doi:10.1097/00004647-199609000-00008
10. Pike VW, Halldin C, Crouzel C, Barre L, Nutt DJ, Osman S, Shah F, Turton DR, Waters SL (1993) Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites—current status. Nucl Med Biol 20:503–525. doi:10.1016/0969-8051(93)90082-6
11. 11C]1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide in mouse plasma and tissue and in human plasma. J Chromatogr B Biomed Sci Appl 736:61–66
12. 11C]PK11195] and its metabolites in humans. Nucl Med Biol 32:307–312. doi:10.1016/j.nucmedbio.2004.12.005
13. 11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol 21:573–581. doi:10.1016/0969-8051(94)90022-1
14. Jaremko Ł, Jaremko M, Giller K, Becker S, Zweckstetter M (2014) Structure of the mitochondrial translocator protein in complex with a diagnostic ligand. Science 343:1363–1366. doi:10.1126/science.1248725
15. 11C](R)-1-(2-chlorophenyl)-N-(1-methylpropyl)-3-isoquinolinecarboxamide in humans; an imaging agent for in vivo assessment of peripheral benzodiazepine receptor activity with positron emission tomography. Eur J Nucl Med Mol Imaging 36:671–682. doi:10.1007/s00259-008-1000-1
16. 11C](R)-PK11195 binding to TSPO in the human brain—a PET study in control subjects. EJNMMI Res 2:15. doi:10.1186/2191-219X-2-15
17. 11C-(R)-PK11195 PET/CT. J Nucl Med 52:33–39. doi:10.2967/jnumed.110.079038
18. Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE (1995) PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer’s disease. J Nucl Med 36:2207–2210
19. Rozemuller JM, van der Valk P, Eikelenboom P (1992) Activated microglia and cerebral amyloid deposits in Alzheimer’s disease. Res Immunol 143:646–649. doi:10.1016/0923-2494(92)80050-U
20. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12:1005–1015. doi:10.1038/nm1484
21. 3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull 18:49–61. doi:10.1016/0361-9230(87)90033-5
22. 11C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab 34:989–994. doi:10.1038/jcbfm.2014.46
23. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP (2012) An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 32:1–5. doi:10.1038/jcbfm.2011.147
24. 11C] flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 15:152–165. doi:10.1038/jcbfm.1995.17
25. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN (2010) Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30:46–50. doi:10.1038/jcbfm.2009.190->
26. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217–227. doi:10.1002/ana.410150302
27. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang S-C, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539. doi:10.1038/sj.jcbfm.9600493
28. 11C] flumazenil kinetics for the estimation of ligand receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11:735–744. doi:10.1038/jcbfm.1991.130
29. 18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24–42. doi:10.1038/jcbfm.1993.6
30. Friedlander G, Kennedy JW, Macias ES, Miller JM (1981) Chapter 5 Equations of radioactive decay and growth. In: Nuclear and radiochemistry, 3rd edn. Wiley, New York, pp 191–205
31. 123I-ADAM. J Nucl Med 49:176–178. doi:10.2967/jnumed.107.046631
32. Slifstein M, Laruelle M (2001) Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 28:595–608. doi:10.1016/S0969-8051(01)00214-1
33. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
34. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70. doi:10.1016/S0092-8674(00)81683-9
35. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461–467. doi:10.1016/S0140-6736(01)05625-2
36. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuromage 6:279–287. doi:10.1006/nimg.1997.0303
37. Herholz K, Patlak CS (1987) The influence of tissue heterogeneity on results of fitting nonlinear model equations to regional tracer uptake curves: with an application to compartmental models used in positron emission tomography. J Cereb Blood Flow Metab 7:214–229. doi:10.1038/jcbfm.1987.47
38. Mahalanobis PC (1936) On the generalised distance in statistics. Proc Natl Inst Sci India 12:49–55
39. Rousseeuw PJ (1987) Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 20:53–65. doi:10.1016/0377-0427(87)90125-7
40. O’Sullivan F (1993) Imaging radiotracer model parameters in PET: a mixture analysis approach. IEEE Trans Med Imaging 12:399–412. doi:10.1109/42.241867
41. Ashburner J, Haslam J, Taylor C, Cunningham VJ, Jones T (1996) A cluster analysis approach for the characterization of dynamic PET data. In: Myers R, Cunningham V, Bailey D, Jones T (eds) Quantification of brain function using PET. Academic Press, San Diego, pp 301–306. doi:10.1016/B978-012389760-2/50061-X. ISBN 0-12-389760-2
42. 11C]PK11195 PET. J Cereb Blood Flow Metab 19:S789
43. Cagnin A, Myers R, Gunn RN, Turkheimer FE, Cunningham VJ, Brooks DJ, Jones T, Banati RB (2000) Imaging activated microglia in the aging human brain. In: Gjedde A, Hansen SB, Knudsen GM, Paulson OB (eds) Physiological imaging of the brain with PET. Academic Press, San Diego, pp 361–367. ISBN 0-12-285751-8
44. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123:2321–2337. doi:10.1093/brain/123.11.2321
45. 11C]PK11195 studies in Alzheimer’s disease and mild cognitive impairment. J Cereb Blood Flow Metab 27:1965–1974. doi:10.1038/sj.jcbfm.9600488
46. 11C]-(R)-PK11195 brain studies. J Nucl Med 48:158–167
47. Chen J, Gunn S, Nixon M, Myers R, Gunn R (2000) A supervised method for PET reference region extraction. In: Arridge S, Todd-Pokropek A (eds) Medical image understanding and analysis MIUA 2000: proceedings of the fourth annual conference. University College London, UK, pp 179–182. ISBN 1-901725-11-1
48. Lawson CL, Hanson RJ (1995) Solving least squares problems. Society for Industrial and Applied Mathematics (SIAM), Philadelphia. ISBN 0-89871-356-0
49. Cunningham VJ, Jones T (1993) Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 13:15–23. doi:10.1038/jcbfm.1993.5
50. 11C]-(R)-PK11195 scans on the High Resolution Research Tomograph (HRRT). Neuroimage 41(suppl. 2):T65. doi:10.1016/j.neuroimage.2008.04.035
51. Drake C, Boutin H, Jones MS, Denes A, McColl BW, Selvarajah JR, Hulme S, Georgiou RF, Hinz R, Gerhard A, Vail A, Prenant C, Julyan P, Maroy R, Brown G, Smigova A, Herholz K, Kassiou M, Crossman D, Francis S, Proctor SD, Russell JC, Hopkins SJ, Tyrrell PJ, Rothwell NJ, Allan SM (2011) Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun 25:1113–1122. doi:10.1016/j.bbi.2011.02.008
52. 11C]PK11195 brain PET studies. In: IEEE Nuclear Sciece Symposium Conference Record, NSS ′08, Dresden, pp 5400–5402
53. 11C]PK11195 in traumatic brain injury. J Nucl Med 50:1975–1979. doi:10.2967/jnumed.109.067512
54. 11C]PK11195 PET: adaptation to rat PET studies. In: 11th international conference on quantification of brain function with PET (BrainPET’13), Shanghai, China, 20–23 May 2013
55. 11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur J Nucl Med Mol Imaging 40:1406–1419. doi:10.1007/s00259-013-2447-2
56. 11C]-(R)PK11195 brain scans: limits of applications. In: 10th international symposium on functional neuroreceptor mapping (NRM) of the living brain, Egmond aan Zee, the Netherlands, 21–24 May 2014. Abstract Book, 117. http://www.vumc.nl/afdelingen-themas/50095/69479/Program-Abstractbook.pdf?version=1
57. 11C]PK11195 brain PET studies. J Cereb Blood Flow Metab 32:1600–1608. doi:10.1038/jcbfm.2012.59
58. 11C]PK11195 brain studies. J Cereb Blood Flow Metab 25:842–851. doi:10.1038/sj.jcbfm.9600092
59. 11C](R)-PK11195 studies. J Cereb Blood Flow Metab 26:1431–1441. doi:10.1038/sj.jcbfm.9600289
60. 11C-(R)-PK11195 in patients with Alzheimer’s disease. J Nucl Med 49:1249–1256. doi:10.2967/jnumed.108.050583
61. 11C]WAY- 100635 for PET. Neuroimage 8: 426–440. doi: 10.1006/nimg.1998.0379
62. 11C]PBR28 brain PET data. J Cereb Blood Flow Metab 34:1060–1069. doi:10.1038/jcbfm.2014.55
63. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57:168–175. doi:10.1002/ana.20338
64. Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, Windhorst AD, Barkhof F, Jonker C, Kloet RW, Lammertsma AA, Scheltens P, van Berckel BN (2012) Microglial activation in healthy aging. Neurobiol Aging 33:1067–1072. doi:10.1016/j.neurobiolaging.2010.09.016
65. 11C-[R]-PK11195 PET. J Neuroinflammation 9:232. doi:10.1186/1742-2094-9-232
66. 11C]vinpocetine. Neuroimage 56:1111–1121. doi:10.1016/j.neuroimage.2011.02.020
67. 18F]-FEPPA. Neuroimage 84:868–875. doi:10.1016/j.neuroimage.2013.09.021
68. 11C]PK11195 positron emission tomography study. Neurobiol Aging 34:128–136. doi:10.1016/j.neurobiolaging.2012.04.021
69. 11C]-(R)-PK11195 positron emission tomography study. Br J Dermatol. doi:10.1111/bjd.13788
70. 18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer’s disease patients. J Cereb Blood Flow Metab 35:766–772. doi:10.1038/jcbfm.2014.261